{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:03:21Z","timestamp":1790035401291,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10147-023-02351-9","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T18:05:25Z","timestamp":1687370725000},"page":"1023-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck"],"prefix":"10.1007","volume":"28","author":[{"given":"Masanobu","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":false,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"2351_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102371","author":"F Ionna","year":"2021","unstructured":"Ionna F, Bossi P, Guida A et al (2021) Recurrent\/metastatic squamous cell carcinoma of the head and neck: a big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13102371","journal-title":"Cancers (Basel)"},{"issue":"19","key":"2351_CR2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"1","key":"2351_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.anl.2019.05.001","volume":"47","author":"T Wakasaki","year":"2020","unstructured":"Wakasaki T, Yasumatsu R, Uchi R et al (2020) Outcome of chemotherapy following nivolumab treatment for recurrent and\/or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx 47(1):116\u2013122. https:\/\/doi.org\/10.1016\/j.anl.2019.05.001","journal-title":"Auris Nasus Larynx"},{"key":"2351_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","volume":"121","author":"K Saleh","year":"2019","unstructured":"Saleh K, Daste A, Martin N et al (2019) Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 121:123\u2013129. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.026","journal-title":"Eur J Cancer"},{"issue":"1","key":"2351_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s40425-019-0672-3","volume":"7","author":"ND Klemen","year":"2019","unstructured":"Klemen ND, Wang M, Feingold PL et al (2019) Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J Immunother Cancer 7(1):196. https:\/\/doi.org\/10.1186\/s40425-019-0672-3","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2351_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1177\/0194599815627637","volume":"154","author":"TD Patel","year":"2016","unstructured":"Patel TD, Marchiano E, Chin OY et al (2016) Utility of surgery\/radiotherapy in distant metastatic head and neck squamous cell carcinoma: a population-based approach. Otolaryngol Head Neck Surg 154(5):868\u2013874. https:\/\/doi.org\/10.1177\/0194599815627637","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"2351_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11864-011-0176-y","volume":"13","author":"KA Price","year":"2012","unstructured":"Price KA, Cohen EE (2012) Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13(1):35\u201346. https:\/\/doi.org\/10.1007\/s11864-011-0176-y","journal-title":"Curr Treat Options Oncol"},{"key":"2351_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctro.2020.04.007","volume":"23","author":"P Bonomo","year":"2020","unstructured":"Bonomo P, Lucidi S, Desideri I et al (2020) Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: a case report. Clin Transl Radiat Oncol 23:16\u201319. https:\/\/doi.org\/10.1016\/j.ctro.2020.04.007","journal-title":"Clin Transl Radiat Oncol"},{"key":"2351_CR9","doi-asserted-by":"publisher","first-page":"117954762090885","DOI":"10.1177\/1179547620908854","volume":"13","author":"N Tsushima","year":"2020","unstructured":"Tsushima N, Shinozaki T, Fujisawa T et al (2020) Salvage reconstructive surgery during nivolumab therapy for a patient with hypopharyngeal cancer. Clin Med Insights Case Rep 13:1179547620908854. https:\/\/doi.org\/10.1177\/1179547620908854","journal-title":"Clin Med Insights Case Rep"},{"issue":"2","key":"2351_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Europ J Cancer (Oxford England ) 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Europ J Cancer (Oxford England )"},{"issue":"3","key":"2351_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2351_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225823","author":"D Harada","year":"2021","unstructured":"Harada D, Takigawa N (2021) Oligoprogression in non-small cell lung cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13225823","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2351_CR13","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41598-021-81666-x","volume":"11","author":"JY Heo","year":"2021","unstructured":"Heo JY, Yoo SH, Suh KJ et al (2021) Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. Sci Rep 11(1):2514. https:\/\/doi.org\/10.1038\/s41598-021-81666-x","journal-title":"Sci Rep"},{"key":"2351_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.089","author":"S Cabezas-Camarero","year":"2021","unstructured":"Cabezas-Camarero S, Merino-Menendez S, Cabrera-Martin MN et al (2021) 71P Safety and efficacy of salvage radiotherapy after progression to checkpoint inhibitors in recurrent and\/or metastatic head and neck cancer. Annals Oncology. https:\/\/doi.org\/10.1016\/j.annonc.2021.10.089","journal-title":"Annals Oncology"},{"issue":"7","key":"2351_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA et al (2017) DNA damage and repair biomarkers of immunotherapy response. Cancer Discov 7(7):675\u2013693. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0226","journal-title":"Cancer Discov"},{"issue":"7683","key":"2351_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","volume":"552","author":"G Germano","year":"2017","unstructured":"Germano G, Lamba S, Rospo G et al (2017) Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552(7683):116\u2013120. https:\/\/doi.org\/10.1038\/nature24673","journal-title":"Nature"},{"issue":"3","key":"2351_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK et al (2018) Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18(3):195\u2013203. https:\/\/doi.org\/10.1038\/nri.2017.145","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2351_CR18","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1172\/JCI96582","volume":"128","author":"X Zheng","year":"2018","unstructured":"Zheng X, Fang Z, Liu X et al (2018) Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104\u20132115. https:\/\/doi.org\/10.1172\/JCI96582","journal-title":"J Clin Invest"},{"issue":"20","key":"2351_CR19","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"issue":"2","key":"2351_CR20","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.ijrobp.2017.06.303","volume":"99","author":"R Samstein","year":"2017","unstructured":"Samstein R, Rimner A, Barker C et al (2017) Combined immune checkpoint blockade and radiation therapy: timing and dose fractionation associated with greatest survival duration among over 750 treated patients. Int J Radiat Oncol Biol Phys 99(2):S129\u2013S130","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"2351_CR21","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167\u20133175. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609","journal-title":"J Clin Oncol"},{"issue":"2","key":"2351_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.anl.2020.02.014","volume":"48","author":"T Ito","year":"2021","unstructured":"Ito T, Sato H, Tsujikawa T et al (2021) Neck dissection prolongs survival in patient with stage IVC hypopharyngeal carcinoma with mixed responses to nivolumab. Auris Nasus Larynx 48(2):322\u2013326. https:\/\/doi.org\/10.1016\/j.anl.2020.02.014","journal-title":"Auris Nasus Larynx"},{"key":"2351_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.07.009","author":"K Sato","year":"2020","unstructured":"Sato K, Ono T, Sato F et al (2020) Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma. Oral Oncol. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.07.009","journal-title":"Oral Oncol"},{"issue":"6","key":"2351_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3747\/co.27.6687","volume":"27","author":"D Forner","year":"2020","unstructured":"Forner D, Horwich P, Trites JR et al (2020) The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review. Curr Oncol 27(6):330\u2013335. https:\/\/doi.org\/10.3747\/co.27.6687","journal-title":"Curr Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02351-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:56:19Z","timestamp":1750481779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02351-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2351"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02351-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"29 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original publication has been updated for inclusion of supplementary information","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author M.T reports grants and personal fees from Ono Pharmaceutical and Bayer, personal fees from Merck Biopharma, MSD, BMS, personal fees from Pfizer, Rakuten Medical, Lilly, Boehringer Ingelheim, Eisai, Chugai Pharmaceutical, Daiichi-Sankyo, Janssen Pharmaceutical, Genmab, Astra Zeneca, Abbvie and Astellas. Other authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}